Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Progression-free Survival as Assessed by BICR Description: Time from randomization until the time of first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first Time frame: Up to 24 months from enrollment of the last patient Measure: Overall survival Description: Time from randomization to death by any cause Time frame: Up to 24 months from enrollment of the last patient. After: Measure: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Description: PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions. Time frame: Up to 20 months Measure: Overall Survival Description: Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates. Time frame: Up to 32 months.
Primary completion date changed
Before: 24 Mar 2025. After: 31 Mar 2025.